**Artificial Intelligence in Precision Oncology: Transforming Cancer Care from Screening to Treatment**

**1. Primary (Main) Title & Combined Structure**> > *A Systematic Review of Diagnostic Imaging, Multimodal Data Integration, and Real-World Implementation in Low-Resource Settings* **2. Alternative Titles (Academic & Technical)*** **Deep Learning and the Cancer Continuum:** Evaluating AI Applications in Early Detection, Pathology, and Personalized Treatment Optimization* **From Pixels to Patients:** A Review of Artificial Intelligence in Oncological Imaging and Clinical Decision Support* **Augmented Oncology:** The Role of Machine Learning in Reducing Diagnostic Delays and Improving Treatment Precision* **Multimodal AI in Cancer Care:** Bridging the Gap Between Algorithmic Performance and Clinical Effectiveness **3. Alternative Titles (Policy, Strategic & Implementation Focus)*** **AI for Equitable Cancer Care:** Policy Frameworks, Infrastructure Requirements, and the Andhra Pradesh Precision Oncology Model* **Technology-Enabled Early Detection:** Deploying AI Screening Tools in Low- and Middle-Income Countries* **The Precision Oncology Ecosystem:** Integrating AI Diagnostics into Public Health Infrastructure for Improved Cancer Outcomes* **Beyond the Algorithm:** Regulatory, Ethical, and Workflow Considerations for AI Adoption in Oncology **4. Alternative Titles (Catchy / Media-Friendly)*** **The AI Oncologist:** How Deep Learning is Reshaping Cancer Detection and Treatment* **Screening at the Speed of AI:** The Promise and Pitfalls of Machine Learning in Cancer Care* **Augmented Diagnosis:** When Artificial Intelligence Meets the Cancer Clinic* **Decoding Cancer with AI:** The Next Frontier in Precision Medicine **5. Subtitles (To accompany the main title)*** *Evidence, Implementation, and Equity Considerations for AI-Driven Cancer Care in India** *Assessing Diagnostic Accuracy, Treatment Prediction, and the Human-AI Collaboration Framework** *A Review of Real-World Deployments and the Path to Scalable, Responsible Adoption** *From Lung Nodule Detection to Precision Therapeutics: A Comprehensive Assessment* **6. Running Headers (For the top of each page in the paper)*** *AI in Precision Oncology: A Review** *Machine Learning in Cancer Care** *AI-Assisted Cancer Detection and Treatment** *Augmented Oncology: Evidence and Implementation* **7. Keywords / Index Terms**Artificial Intelligence, Precision Oncology, Deep Learning, Cancer Screening, Diagnostic Imaging, Multimodal Data Integration, Clinical Decision Support, Human-AI Collaboration, Health Equity, Andhra Pradesh, Low-Resource Settings, Regulatory Frameworks. --- ### Part 2: Detailed Description of the Research Paper **Abstract**The escalating global cancer burden, compounded by disparities in healthcare access, presents a critical challenge to oncological care. Artificial Intelligence (AI) is rapidly reshaping the cancer care continuum—from early detection to personalized treatment—by leveraging capabilities in image recognition, multimodal data integration, and clinical decision support. This paper systematically reviews key AI applications in oncology, including diagnostic imaging, pathology analysis, treatment optimization, and toxicity prediction. It contextualizes these advancements within real-world implementations, such as Andhra Pradesh's newly launched precision oncology ecosystem and the deployment of AI-powered pulmonary nodule screening. The review finds that while AI achieves performance comparable to specialist physicians in specific diagnostic tasks, its clinical value remains constrained by limited external validation, data heterogeneity, and the maturity of human-AI collaboration workflows. We argue that AI's appropriate role in oncology is to augment—not replace—clinical judgment, and that scalable impact depends on coordinated progress in infrastructure integration, regulatory frameworks, and continuous performance monitoring. **1. Introduction**Cancer remains a leading cause of mortality worldwide. Delayed diagnosis and limited access to treatment are key drivers of poor outcomes. In low- and middle-income countries such as India, patients with common malignancies—including lung and breast cancer—are often diagnosed at advanced stages, severely narrowing the window for effective intervention. In 2023, Andhra Pradesh recorded over 71,000 new cancer cases, with the government allocating ₹72 crore to upgrade cancer care infrastructure. The state's recent initiatives—establishing a precision oncology ecosystem with international collaboration and deploying AI-based lung cancer screening—reflect a growing recognition that technology-enabled early detection and precision medicine can address structural gaps in oncology care. This paper reviews the evidence base for AI in oncology and examines the policy and implementation conditions required for its responsible deployment. **2. AI Applications Across the Cancer Care Continuum*** **Screening and Early Detection:** Medical imaging is the most mature domain for AI in oncology. Deep learning models have demonstrated performance comparable to radiologists in detecting pulmonary nodules on low-dose CT scans, with the potential to reduce false positives and streamline radiology workflows. In Andhra Pradesh, AI-assisted lung cancer screening has been introduced specifically to enable earlier detection among high-risk populations. Beyond imaging, AI is being applied to pathology and genomics. Computational pathology tools can identify malignant cells in digitized histology slides with high sensitivity, while genomic AI models integrate mutation profiles with clinical data to stratify patients for targeted therapies. Multi-omics integration represents a frontier in precision oncology, though clinical validation remains limited.* **Treatment Optimization and Toxicity Prediction:** AI's role extends beyond diagnosis. Machine learning models trained on electronic health records, imaging data, and genomic profiles can predict treatment response and adverse events, supporting individualized therapy selection. In radiation oncology, AI-assisted contouring and treatment planning reduce inter-observer variability and planning time. The Andhra Pradesh precision oncology ecosystem, developed in collaboration with international partners, aims to integrate AI-driven diagnostics and treatment recommendations into the state's cancer care network. These initiatives target both public and private healthcare delivery, with a focus on improving affordability and accessibility. **3. Real-World Implementation: The Andhra Pradesh Case*** **Infrastructure and Policy Context:** Andhra Pradesh's approach combines infrastructure investment with technology adoption. The state has allocated significant resources to upgrade cancer care facilities and has explicitly positioned AI as a tool for early detection and precision treatment. The deployment of AI-based lung cancer screening is notable for its population-level orientation—targeting high-risk individuals rather than relying solely on opportunistic detection.* **Implementation Challenges:** Real-world deployment reveals several constraints. Data heterogeneity across public and private facilities complicates model generalization. External validation of AI tools in local populations is often lacking, raising concerns about performance degradation when models trained on one demographic are applied to another. Workflow integration—ensuring that AI outputs are actionable within clinical pathways—remains a practical bottleneck. The state's initiative also highlights the need for regulatory and ethical frameworks. AI-assisted diagnosis requires clear accountability structures, clinician training, and mechanisms for monitoring model drift over time. **4. Limitations and Critical Perspectives*** **Evidence Gaps:** Most AI oncology studies are retrospective and single-center. Prospective, multi-site validation is scarce, particularly in low-resource settings. Publication bias toward positive results further limits the evidence base. The gap between algorithmic performance in controlled studies and clinical effectiveness in diverse populations remains substantial.* **Human-AI Collaboration:** AI is not a substitute for clinical judgment. The most effective deployment models position AI as a decision-support tool, with clinicians retaining final authority. This requires designing interfaces that communicate model uncertainty clearly and training clinicians to interpret AI outputs critically. Over-reliance on AI—automation bias—is a recognized risk.* **Equity and Access:** AI tools are often developed in high-income settings and may not generalize to populations with different disease epidemiology, imaging protocols, or healthcare infrastructure. Without deliberate efforts to validate and adapt models locally, AI risks widening rather than narrowing health disparities. **5. Policy and Research Recommendations**1. **Mandate external validation** of AI diagnostic tools in target populations before clinical deployment.2. **Invest in data infrastructure**—standardized imaging protocols, interoperable health records, and secure data-sharing frameworks—to enable robust model development and monitoring.3. **Develop clinician training programs** focused on AI literacy, uncertainty interpretation, and human-AI workflow integration.4. **Establish regulatory pathways** for AI-based medical devices that include post-market surveillance and performance reporting.5. **Prioritize equity-oriented research** to ensure AI tools are validated across demographic and socioeconomic strata. **6. Conclusion**Artificial intelligence holds substantial promise for improving cancer outcomes through earlier detection, more precise diagnosis, and personalized treatment. The Andhra Pradesh initiatives demonstrate political will to integrate AI into oncology care at scale. However, the transition from promising algorithms to reliable clin

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24151315
Primary Topic
AI in cancer detection
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

**Artificial Intelligence in Precision Oncology: Transforming Cancer Care from Screening to Treatment**

Sudhakar Geruganti
Zenodo (CERN European Organization for Nuclear Research)
AI in cancer detection
preprint

**Artificial Intelligence in Precision Oncology: Transforming Cancer Care from Screening to Treatment**

Sudhakar Geruganti
preprint en

Abstract

**1. Primary (Main) Title & Combined Structure**> > *A Systematic Review of Diagnostic Imaging, Multimodal Data Integration, and Real-World Implementation in Low-Resource Settings* **2. Alternative Titles (Academic & Technical)*** **Deep Learning and the Cancer Continuum:** Evaluating AI Applications in Early Detection, Pathology, and Personalized Treatment Optimization* **From Pixels to Patients:** A Review of Artificial Intelligence in Oncological Imaging and Clinical Decision Support* **Augmented Oncology:** The Role of Machine Learning in Reducing Diagnostic Delays and Improving Treatment Precision* **Multimodal AI in Cancer Care:** Bridging the Gap Between Algorithmic Performance and Clinical Effectiveness **3. Alternative Titles (Policy, Strategic & Implementation Focus)*** **AI for Equitable Cancer Care:** Policy Frameworks, Infrastructure Requirements, and the Andhra Pradesh Precision Oncology Model* **Technology-Enabled Early Detection:** Deploying AI Screening Tools in Low- and Middle-Income Countries* **The Precision Oncology Ecosystem:** Integrating AI Diagnostics into Public Health Infrastructure for Improved Cancer Outcomes* **Beyond the Algorithm:** Regulatory, Ethical, and Workflow Considerations for AI Adoption in Oncology **4. Alternative Titles (Catchy / Media-Friendly)*** **The AI Oncologist:** How Deep Learning is Reshaping Cancer Detection and Treatment* **Screening at the Speed of AI:** The Promise and Pitfalls of Machine Learning in Cancer Care* **Augmented Diagnosis:** When Artificial Intelligence Meets the Cancer Clinic* **Decoding Cancer with AI:** The Next Frontier in Precision Medicine **5. Subtitles (To accompany the main title)*** *Evidence, Implementation, and Equity Considerations for AI-Driven Cancer Care in India** *Assessing Diagnostic Accuracy, Treatment Prediction, and the Human-AI Collaboration Framework** *A Review of Real-World Deployments and the Path to Scalable, Responsible Adoption** *From Lung Nodule Detection to Precision Therapeutics: A Comprehensive Assessment* **6. Running Headers (For the top of each page in the paper)*** *AI in Precision Oncology: A Review** *Machine Learning in Cancer Care** *AI-Assisted Cancer Detection and Treatment** *Augmented Oncology: Evidence and Implementation* **7. Keywords / Index Terms**Artificial Intelligence, Precision Oncology, Deep Learning, Cancer Screening, Diagnostic Imaging, Multimodal Data Integration, Clinical Decision Support, Human-AI Collaboration, Health Equity, Andhra Pradesh, Low-Resource Settings, Regulatory Frameworks. --- ### Part 2: Detailed Description of the Research Paper **Abstract**The escalating global cancer burden, compounded by disparities in healthcare access, presents a critical challenge to oncological care. Artificial Intelligence (AI) is rapidly reshaping the cancer care continuum—from early detection to personalized treatment—by leveraging capabilities in image recognition, multimodal data integration, and clinical decision support. This paper systematically reviews key AI applications in oncology, including diagnostic imaging, pathology analysis, treatment optimization, and toxicity prediction. It contextualizes these advancements within real-world implementations, such as Andhra Pradesh's newly launched precision oncology ecosystem and the deployment of AI-powered pulmonary nodule screening. The review finds that while AI achieves performance comparable to specialist physicians in specific diagnostic tasks, its clinical value remains constrained by limited external validation, data heterogeneity, and the maturity of human-AI collaboration workflows. We argue that AI's appropriate role in oncology is to augment—not replace—clinical judgment, and that scalable impact depends on coordinated progress in infrastructure integration, regulatory frameworks, and continuous performance monitoring. **1. Introduction**Cancer remains a leading cause of mortality worldwide. Delayed diagnosis and limited access to treatment are key drivers of poor outcomes. In low- and middle-income countries such as India, patients with common malignancies—including lung and breast cancer—are often diagnosed at advanced stages, severely narrowing the window for effective intervention. In 2023, Andhra Pradesh recorded over 71,000 new cancer cases, with the government allocating ₹72 crore to upgrade cancer care infrastructure. The state's recent initiatives—establishing a precision oncology ecosystem with international collaboration and deploying AI-based lung cancer screening—reflect a growing recognition that technology-enabled early detection and precision medicine can address structural gaps in oncology care. This paper reviews the evidence base for AI in oncology and examines the policy and implementation conditions required for its responsible deployment. **2. AI Applications Across the Cancer Care Continuum*** **Screening and Early Detection:** Medical imaging is the most mature domain for AI in oncology. Deep learning models have demonstrated performance comparable to radiologists in detecting pulmonary nodules on low-dose CT scans, with the potential to reduce false positives and streamline radiology workflows. In Andhra Pradesh, AI-assisted lung cancer screening has been introduced specifically to enable earlier detection among high-risk populations. Beyond imaging, AI is being applied to pathology and genomics. Computational pathology tools can identify malignant cells in digitized histology slides with high sensitivity, while genomic AI models integrate mutation profiles with clinical data to stratify patients for targeted therapies. Multi-omics integration represents a frontier in precision oncology, though clinical validation remains limited.* **Treatment Optimization and Toxicity Prediction:** AI's role extends beyond diagnosis. Machine learning models trained on electronic health records, imaging data, and genomic profiles can predict treatment response and adverse events, supporting individualized therapy selection. In radiation oncology, AI-assisted contouring and treatment planning reduce inter-observer variability and planning time. The Andhra Pradesh precision oncology ecosystem, developed in collaboration with international partners, aims to integrate AI-driven diagnostics and treatment recommendations into the state's cancer care network. These initiatives target both public and private healthcare delivery, with a focus on improving affordability and accessibility. **3. Real-World Implementation: The Andhra Pradesh Case*** **Infrastructure and Policy Context:** Andhra Pradesh's approach combines infrastructure investment with technology adoption. The state has allocated significant resources to upgrade cancer care facilities and has explicitly positioned AI as a tool for early detection and precision treatment. The deployment of AI-based lung cancer screening is notable for its population-level orientation—targeting high-risk individuals rather than relying solely on opportunistic detection.* **Implementation Challenges:** Real-world deployment reveals several constraints. Data heterogeneity across public and private facilities complicates model generalization. External validation of AI tools in local populations is often lacking, raising concerns about performance degradation when models trained on one demographic are applied to another. Workflow integration—ensuring that AI outputs are actionable within clinical pathways—remains a practical bottleneck. The state's initiative also highlights the need for regulatory and ethical frameworks. AI-assisted diagnosis requires clear accountability structures, clinician training, and mechanisms for monitoring model drift over time. **4. Limitations and Critical Perspectives*** **Evidence Gaps:** Most AI oncology studies are retrospective and single-center. Prospective, multi-site validation is scarce, particularly in low-resource settings. Publication bias toward positive results further limits the evidence base. The gap between algorithmic performance in controlled studies and clinical effectiveness in diverse populations remains substantial.* **Human-AI Collaboration:** AI is not a substitute for clinical judgment. The most effective deployment models position AI as a decision-support tool, with clinicians retaining final authority. This requires designing interfaces that communicate model uncertainty clearly and training clinicians to interpret AI outputs critically. Over-reliance on AI—automation bias—is a recognized risk.* **Equity and Access:** AI tools are often developed in high-income settings and may not generalize to populations with different disease epidemiology, imaging protocols, or healthcare infrastructure. Without deliberate efforts to validate and adapt models locally, AI risks widening rather than narrowing health disparities. **5. Policy and Research Recommendations**1. **Mandate external validation** of AI diagnostic tools in target populations before clinical deployment.2. **Invest in data infrastructure**—standardized imaging protocols, interoperable health records, and secure data-sharing frameworks—to enable robust model development and monitoring.3. **Develop clinician training programs** focused on AI literacy, uncertainty interpretation, and human-AI workflow integration.4. **Establish regulatory pathways** for AI-based medical devices that include post-market surveillance and performance reporting.5. **Prioritize equity-oriented research** to ensure AI tools are validated across demographic and socioeconomic strata. **6. Conclusion**Artificial intelligence holds substantial promise for improving cancer outcomes through earlier detection, more precise diagnosis, and personalized treatment. The Andhra Pradesh initiatives demonstrate political will to integrate AI into oncology care at scale. However, the transition from promising algorithms to reliable clin

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
AI in cancer detection
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon